IL189628A0 - An anti-ca6 monoclonal antibody and a ca6 antigen specific cytotoxic conjugate containing the same - Google Patents
An anti-ca6 monoclonal antibody and a ca6 antigen specific cytotoxic conjugate containing the sameInfo
- Publication number
- IL189628A0 IL189628A0 IL189628A IL18962808A IL189628A0 IL 189628 A0 IL189628 A0 IL 189628A0 IL 189628 A IL189628 A IL 189628A IL 18962808 A IL18962808 A IL 18962808A IL 189628 A0 IL189628 A0 IL 189628A0
- Authority
- IL
- Israel
- Prior art keywords
- same
- monoclonal antibody
- antigen specific
- specific cytotoxic
- conjugate containing
- Prior art date
Links
- 239000000427 antigen Substances 0.000 title 1
- 102000036639 antigens Human genes 0.000 title 1
- 108091007433 antigens Proteins 0.000 title 1
- 231100000433 cytotoxic Toxicity 0.000 title 1
- 230000001472 cytotoxic effect Effects 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/68033—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a maytansine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6875—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody being a hybrid immunoglobulin
- A61K47/6877—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody being a hybrid immunoglobulin the antibody being an immunoglobulin containing regions, domains or residues from different species
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
- C07K16/464—Igs containing CDR-residues from one specie grafted between FR-residues from another
- C07K16/465—Igs containing CDR-residues from one specie grafted between FR-residues from another with additional modified FR-residues
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cell Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/US2005/030115 WO2007024222A1 (en) | 2005-08-22 | 2005-08-22 | A ca6 antigen-specific cytotoxic conjugate and methods of using the same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL189628A0 true IL189628A0 (en) | 2008-06-05 |
Family
ID=37771883
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL189628A IL189628A0 (en) | 2005-08-22 | 2008-02-20 | An anti-ca6 monoclonal antibody and a ca6 antigen specific cytotoxic conjugate containing the same |
| IL238798A IL238798A0 (en) | 2005-08-22 | 2015-05-13 | A ca6 antigen specific cytotoxic conjugate and methods of usinng the same |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL238798A IL238798A0 (en) | 2005-08-22 | 2015-05-13 | A ca6 antigen specific cytotoxic conjugate and methods of usinng the same |
Country Status (13)
| Country | Link |
|---|---|
| EP (1) | EP1917034A4 (en) |
| JP (1) | JP2009504193A (en) |
| CN (1) | CN101242855A (en) |
| AU (1) | AU2005335743A1 (en) |
| BR (1) | BRPI0520509A2 (en) |
| CA (1) | CA2615761A1 (en) |
| EA (1) | EA020130B9 (en) |
| EC (1) | ECSP088241A (en) |
| HK (1) | HK1211965A1 (en) |
| IL (2) | IL189628A0 (en) |
| MX (1) | MX2008002607A (en) |
| NO (1) | NO20080893L (en) |
| WO (1) | WO2007024222A1 (en) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014089177A2 (en) | 2012-12-04 | 2014-06-12 | Massachusetts Institute Of Technology | Compounds, conjugates and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines |
| HUE037456T2 (en) * | 2013-02-05 | 2018-08-28 | Sanofi Sa | Immuno imaging agent for use with antibody-drug conjugate therapy |
| JP2016515093A (en) * | 2013-02-05 | 2016-05-26 | サノフイ | Immunoimaging agents for use with antibody-drug conjugate therapy |
| WO2014122529A1 (en) * | 2013-02-05 | 2014-08-14 | Sanofi | Immuno imaging agent for use with antibody-drug conjugate therapy |
| US9989524B2 (en) | 2013-02-05 | 2018-06-05 | Sanofi | Immuno imaging agent for use with antibody-drug conjugate therapy |
| US20160347856A1 (en) * | 2013-08-02 | 2016-12-01 | Sanofi | Use of Anti-MUC1 Maytansinoid Immunoconjugate Antibody for the Treatment of Solid Tumors |
| CN106999604B (en) | 2014-09-02 | 2021-08-03 | 伊缪诺金公司 | Methods for formulating antibody drug conjugate compositions |
| ES2815353T3 (en) | 2014-09-03 | 2021-03-29 | Immunogen Inc | Cytotoxic benzodiazepine derivatives |
| EP3189057A1 (en) | 2014-09-03 | 2017-07-12 | ImmunoGen, Inc. | Cytotoxic benzodiazepine derivatives |
| JP2019501139A (en) | 2015-11-25 | 2019-01-17 | イミュノジェン・インコーポレーテッド | Pharmaceutical formulations and uses thereof |
| WO2017197045A1 (en) | 2016-05-11 | 2017-11-16 | Movassaghi Mohammad | Convergent and enantioselective total synthesis of communesin analogs |
| CN110366431B (en) | 2017-02-28 | 2023-07-18 | 伊缪诺金公司 | Maytansinoid derivatives with self-decomposing peptide linkers and conjugates thereof |
| WO2018195243A1 (en) | 2017-04-20 | 2018-10-25 | Immunogen, Inc. | Cytotoxic benzodiazepine derivatives and conjugates thereof |
| WO2018209239A1 (en) | 2017-05-11 | 2018-11-15 | Massachusetts Institute Of Technology | Potent agelastatin derivatives as modulators for cancer invasion and metastasis |
| US10640508B2 (en) | 2017-10-13 | 2020-05-05 | Massachusetts Institute Of Technology | Diazene directed modular synthesis of compounds with quaternary carbon centers |
| JP2021508714A (en) | 2017-12-28 | 2021-03-11 | イミュノジェン・インコーポレーテッド | Benzodiazepine derivative |
| WO2020247054A1 (en) | 2019-06-05 | 2020-12-10 | Massachusetts Institute Of Technology | Compounds, conjugates, and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines and uses thereof |
| US12030888B2 (en) | 2021-02-24 | 2024-07-09 | Massachusetts Institute Of Technology | Himastatin derivatives, and processes of preparation thereof, and uses thereof |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6596503B1 (en) * | 2000-08-18 | 2003-07-22 | East Carolina University | Monoclonal antibody DS6, tumor-associated antigen CA6, and methods of use thereof |
| EP2281577B1 (en) * | 2003-05-14 | 2016-11-16 | ImmunoGen, Inc. | Drug conjugate composition |
| ES2360403T3 (en) * | 2003-07-21 | 2011-06-03 | Immunogen, Inc. | SPECIFIC CYTOTOX CONJUGATE FOR THE CA6 ANTIGEN AND METHODS TO USE THE SAME. |
-
2005
- 2005-08-22 CA CA002615761A patent/CA2615761A1/en not_active Abandoned
- 2005-08-22 WO PCT/US2005/030115 patent/WO2007024222A1/en active Application Filing
- 2005-08-22 AU AU2005335743A patent/AU2005335743A1/en not_active Abandoned
- 2005-08-22 BR BRPI0520509-3A patent/BRPI0520509A2/en not_active Application Discontinuation
- 2005-08-22 EP EP05788869A patent/EP1917034A4/en not_active Withdrawn
- 2005-08-22 EA EA200800642A patent/EA020130B9/en not_active IP Right Cessation
- 2005-08-22 CN CNA200580051368XA patent/CN101242855A/en active Pending
- 2005-08-22 JP JP2008527882A patent/JP2009504193A/en not_active Withdrawn
- 2005-08-22 MX MX2008002607A patent/MX2008002607A/en not_active Application Discontinuation
-
2008
- 2008-02-20 NO NO20080893A patent/NO20080893L/en not_active Application Discontinuation
- 2008-02-20 IL IL189628A patent/IL189628A0/en unknown
- 2008-03-05 EC EC2008008241A patent/ECSP088241A/en unknown
-
2015
- 2015-05-13 IL IL238798A patent/IL238798A0/en unknown
- 2015-12-31 HK HK15112923.0A patent/HK1211965A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ECSP088241A (en) | 2008-04-28 |
| HK1211965A1 (en) | 2016-06-03 |
| AU2005335743A1 (en) | 2007-03-01 |
| EP1917034A1 (en) | 2008-05-07 |
| MX2008002607A (en) | 2008-03-19 |
| EA020130B1 (en) | 2014-08-29 |
| CA2615761A1 (en) | 2007-03-01 |
| EP1917034A4 (en) | 2009-04-29 |
| BRPI0520509A2 (en) | 2009-05-12 |
| EA200800642A1 (en) | 2008-08-29 |
| JP2009504193A (en) | 2009-02-05 |
| NO20080893L (en) | 2008-05-22 |
| CN101242855A (en) | 2008-08-13 |
| EA020130B9 (en) | 2014-10-30 |
| WO2007024222A1 (en) | 2007-03-01 |
| IL238798A0 (en) | 2015-06-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL189628A0 (en) | An anti-ca6 monoclonal antibody and a ca6 antigen specific cytotoxic conjugate containing the same | |
| IL272883A (en) | Monoclonal antibodies and uses thereof | |
| IL179672A (en) | Human monoclonal anti-cd3 antibodies | |
| IL187710A0 (en) | Anti-trkb monoclonal antibodies and uses thereof | |
| ZA200607705B (en) | Antibody calicheamicin conjugates | |
| IL176755A0 (en) | M-csf-specific monoclonal antibody and uses thereof | |
| HK1098825A1 (en) | Human monoclonal antibodies against cd20 | |
| IL206710A0 (en) | Il-31 monoclonal antibodies | |
| IL190502A0 (en) | Anti-addl monoclonal antibody and use thereof | |
| HK1111177A1 (en) | M-csf specific monoclonal antibody and uses thereof m-csf | |
| EP1717250A4 (en) | Monoclonal antibody and use thereof | |
| ZA200802051B (en) | Anti-CD3 antibody formulations | |
| WO2006031653A3 (en) | Humanized anti-5t4 antibodies and anti-5t4 antibody / calicheamicin conjugates | |
| EP1658095A4 (en) | De-immunized anti-cd3 antibody | |
| IL180152A0 (en) | Chimeric and humanised monoclonal antibodies against inteleukin-13 | |
| IL204159A (en) | Cysteine engineered anti-tenb2 antibodies and antibody drug conjugates | |
| EP2233501A4 (en) | Humanized anti-cd34 monoclonal antibody, the preparation and uses thereof | |
| IL185781A0 (en) | Antibodies against candida antigens | |
| HK1100848A1 (en) | Anti-human tenascin monoclonal antibody | |
| EP2077325A4 (en) | Monoclonal antibody and use thereof | |
| EP2149582A4 (en) | Osteopontin functional epitopes, monoclonal antibodies against the epitopes and uses thereof | |
| HK1115598A1 (en) | Humanised antibodies specific for nogo-a and pharmaceutical uses thereof | |
| ZA200707838B (en) | Antibodies against Candida antigens | |
| ZA200706336B (en) | CD20 antibody variants and uses thereof | |
| ZA200800047B (en) | Humanised antibodies specific for NOGO-A and pharmaceutical uses thereof |